ACQUISITION (Details 1) (USD $)	Dec. 29, 2011
Cash and cash equivalents	$ 10,386
Other assets	90,770
In-process research and development acquired	3,902,300
Total identifiable assets	4,003,456
Accounts payable and accrued expenses	197,191
Total identifiable liabilities	4,424,609
Net identifiable assets (liabilities)	(421,153)
Goodwill	799,391
Total	378,238
Icon and Swiss Pharma [Member]
Notes payable	939,718
Excluding Icon and Swiss Pharma [Member]
Notes payable	$ 3,287,700